MX2021004474A - Compuestos que contienen deuterio. - Google Patents
Compuestos que contienen deuterio.Info
- Publication number
- MX2021004474A MX2021004474A MX2021004474A MX2021004474A MX2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A MX 2021004474 A MX2021004474 A MX 2021004474A
- Authority
- MX
- Mexico
- Prior art keywords
- deuterium
- compounds containing
- containing deuterium
- compounds
- formula
- Prior art date
Links
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229910052805 deuterium Inorganic materials 0.000 title abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816998.7A GB201816998D0 (en) | 2018-10-18 | 2018-10-18 | Compounds |
| GBGB1909695.7A GB201909695D0 (en) | 2019-07-05 | 2019-07-05 | Compounds |
| PCT/EP2019/078250 WO2020079165A1 (en) | 2018-10-18 | 2019-10-17 | Compounds containing deuterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004474A true MX2021004474A (es) | 2021-08-24 |
Family
ID=68290247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004474A MX2021004474A (es) | 2018-10-18 | 2019-10-17 | Compuestos que contienen deuterio. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12152087B2 (enExample) |
| EP (1) | EP3866931B1 (enExample) |
| JP (2) | JP7603199B2 (enExample) |
| KR (1) | KR102848971B1 (enExample) |
| CN (1) | CN112930214B (enExample) |
| AU (1) | AU2019362389B2 (enExample) |
| BR (1) | BR112021007060A2 (enExample) |
| CA (1) | CA3116198A1 (enExample) |
| DK (1) | DK3866931T3 (enExample) |
| ES (1) | ES2942468T3 (enExample) |
| FI (1) | FI3866931T3 (enExample) |
| HU (1) | HUE061801T2 (enExample) |
| IL (1) | IL282231B2 (enExample) |
| MA (1) | MA53904A (enExample) |
| MX (1) | MX2021004474A (enExample) |
| PL (1) | PL3866931T3 (enExample) |
| SG (1) | SG11202103726RA (enExample) |
| WO (1) | WO2020079165A1 (enExample) |
| ZA (1) | ZA202102492B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| ES3034388T3 (en) * | 2021-06-01 | 2025-08-18 | Synthon Bv | Process for making melflufen or a salt thereof |
| JP2024524552A (ja) | 2021-07-08 | 2024-07-05 | オンコペプティデス エービー | 多発性骨髄腫の治療に使用するためのメルフルフェン |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
| WO2026057823A1 (en) * | 2024-09-13 | 2026-03-19 | Oncopeptides Ab | Bis-chloroethylamino derivatives for treating leukemia |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| DK2701720T3 (en) * | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| SMT202000058T1 (it) * | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| JP2016506957A (ja) | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｍａｔ２のベンゾキノロン阻害剤 |
| ES2901752T3 (es) * | 2013-02-05 | 2022-03-23 | Teva Pharmaceuticals Int Gmbh | Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos |
| WO2015084622A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| CN110229159B (zh) | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| AU2016229949B2 (en) | 2015-03-06 | 2021-04-08 | Auspex Pharmaceuticals Llc | Methods for the treatment of abnormal involuntary movement disorders |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
-
2019
- 2019-10-17 US US17/286,002 patent/US12152087B2/en active Active
- 2019-10-17 SG SG11202103726RA patent/SG11202103726RA/en unknown
- 2019-10-17 WO PCT/EP2019/078250 patent/WO2020079165A1/en not_active Ceased
- 2019-10-17 HU HUE19790194A patent/HUE061801T2/hu unknown
- 2019-10-17 FI FIEP19790194.5T patent/FI3866931T3/fi active
- 2019-10-17 MX MX2021004474A patent/MX2021004474A/es unknown
- 2019-10-17 MA MA053904A patent/MA53904A/fr unknown
- 2019-10-17 IL IL282231A patent/IL282231B2/en unknown
- 2019-10-17 DK DK19790194.5T patent/DK3866931T3/da active
- 2019-10-17 KR KR1020217011490A patent/KR102848971B1/ko active Active
- 2019-10-17 CN CN201980068384.1A patent/CN112930214B/zh active Active
- 2019-10-17 EP EP19790194.5A patent/EP3866931B1/en active Active
- 2019-10-17 ES ES19790194T patent/ES2942468T3/es active Active
- 2019-10-17 PL PL19790194.5T patent/PL3866931T3/pl unknown
- 2019-10-17 JP JP2021521145A patent/JP7603199B2/ja active Active
- 2019-10-17 CA CA3116198A patent/CA3116198A1/en active Pending
- 2019-10-17 AU AU2019362389A patent/AU2019362389B2/en active Active
- 2019-10-17 BR BR112021007060-5A patent/BR112021007060A2/pt unknown
-
2021
- 2021-04-15 ZA ZA2021/02492A patent/ZA202102492B/en unknown
-
2024
- 2024-07-03 JP JP2024107578A patent/JP2024150488A/ja active Pending
- 2024-10-16 US US18/917,773 patent/US20250115637A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7603199B2 (ja) | 2024-12-20 |
| FI3866931T3 (fi) | 2023-05-10 |
| CN112930214A (zh) | 2021-06-08 |
| EP3866931B1 (en) | 2023-02-15 |
| IL282231A (en) | 2021-05-31 |
| MA53904A (fr) | 2021-08-25 |
| ES2942468T3 (es) | 2023-06-01 |
| KR102848971B1 (ko) | 2025-08-21 |
| US20250115637A1 (en) | 2025-04-10 |
| HUE061801T2 (hu) | 2023-08-28 |
| BR112021007060A2 (pt) | 2021-07-20 |
| KR20210078487A (ko) | 2021-06-28 |
| EP3866931A1 (en) | 2021-08-25 |
| IL282231B2 (en) | 2025-07-01 |
| US12152087B2 (en) | 2024-11-26 |
| JP2024150488A (ja) | 2024-10-23 |
| CN112930214B (zh) | 2025-05-16 |
| US20210388024A1 (en) | 2021-12-16 |
| AU2019362389A1 (en) | 2021-06-03 |
| WO2020079165A1 (en) | 2020-04-23 |
| IL282231B1 (en) | 2025-03-01 |
| JP2022512736A (ja) | 2022-02-07 |
| PL3866931T3 (pl) | 2023-06-19 |
| DK3866931T3 (da) | 2023-04-24 |
| CA3116198A1 (en) | 2020-04-23 |
| SG11202103726RA (en) | 2021-05-28 |
| ZA202102492B (en) | 2024-04-24 |
| AU2019362389B2 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004474A (es) | Compuestos que contienen deuterio. | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| EP4474017A3 (en) | New heterocyclic compounds | |
| PH12020500673A1 (en) | Compounds | |
| WO2017019804A3 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| SA522431429B1 (ar) | Sting مركبات كبيرة الحلقات كمساعِدات وطرق واستخداماتها | |
| MX418519B (es) | Inhibidores selectivos de jak1 | |
| ZA202309446B (en) | Rapamycin analogs and uses thereof | |
| PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| SG11201810704WA (en) | Sulfonamide compound or salt thereof | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AU2019328154A8 (en) | Pyrazole compounds, pharmaceutical compositions thereof and use thereof | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| MX2018001925A (es) | Composiciones que comprenden compuestos triciclicos heterociclicos. | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX386501B (es) | Compuestos terapeuticos y sus metodos de uso | |
| PH12022551403A1 (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine. |